BBCNEWS BBC News at Six June 4, 2024 17:07:00
Was the first drug ever to show it could slow the progress of alzheimer's disease. dementia researchers say we are now entering a new era, where alzheimer's disease is treatable. so what we now need when we have the full results will be regulators to make quick decisions so that the patients that could benefit from these treatments are able to benefit. we don't know how much donanemab will cost, but lecanemab is over £20,000 a year per patient in the us, where it is licensed. dementia specialists say we'll need a complete overhaul of alzheimer's services, including access to specialist brain ...